Physician

Vandana Karri, MD

According to 2025 Medicare claims, Vandana Karri, MD (NPI: 1932188562) practices hematology/oncology in the Roanoke, VA market, with the plurality of this provider's patient population coming from Roanoke City, VA. This provider's primary affiliated billing organization is LEWIS GALE PHYSICIANS LLC (NPI: 1902977705; TIN: 061755234) and primary practice location at 24153-7357. Karri is affiliated with the Doctors Connected (ACO ID: A4949), participating under the MSSP model.

Karri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 523 traditional Medicare patients, billed 37,558 HCPCS/CPT codes, and received $676,744 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,269 prescription claims across 237 beneficiaries totaling $3,996,337 in drug costs, led by Revlimid (Lenalidomide). DME data shows 77 claims. Open Payments data shows 115 records totaling $3,101. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $398,643 and ending at $676,744. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,331,118 to $3,996,337. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,408 to $508.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	504	38,026	$398,643
2016	522	46,921	$508,718
2017	533	29,621	$434,723
2018	541	27,820	$516,621
2019	569	19,038	$443,795
2020	500	20,491	$561,621
2021	558	22,279	$460,279
2022	561	23,630	$474,989
2023	541	22,542	$441,672
2024	523	37,558	$676,744

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	141	895	$1,331,118
2016	150	945	$1,561,218
2017	155	959	$1,804,119
2018	168	1,137	$2,193,318
2019	162	952	$2,523,712
2020	183	1,351	$3,655,763
2021	213	1,230	$3,053,800
2022	213	1,127	$3,466,912
2023	228	1,185	$3,423,265
2024	237	1,269	$3,996,337

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	38	$35,967
2016	N/R	68	$36,844
2017	N/R	71	$19,632
2018	N/R	114	$7,070
2019	N/R	72	$5,028
2020	N/R	75	$3,655
2021	N/R	N/R	N/R
2022	N/R	102	$2,200
2023	N/R	69	$7,091
2024	N/R	77	$1,819

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	56	101	$134
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	95	95	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	209	669	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	336	669	$63
96372	Injection of drug or substance under skin or into muscle	78	286	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,015	$605,582
Lenalidomide	Lenalidomide	48	1,218	$592,252
Brukinsa	Zanubrutinib	36	1,080	$526,012
Jakafi	Ruxolitinib Phosphate	38	1,116	$506,074
Jaypirca	Pirtobrutinib	16	474	$329,003

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	34	$1,217
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	30	$376
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	13	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	115	$3,101	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vandana Karri, MD?

Tedicare shows public-source Medicare data for Vandana Karri, MD (NPI 1932188562), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vandana Karri, MD have ACO affiliation data?

Vandana Karri, MD is shown with ACO affiliation data for Doctors Connected (MSSP, ACO ID A4949).

What billing organization is linked to Vandana Karri, MD?

Vandana Karri, MD is linked to LEWIS GALE PHYSICIANS LLC (billing NPI 1902977705) in the available physician profile data.

Does Vandana Karri, MD have Open Payments data?

Vandana Karri, MD has 115 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.